Prospects for the prevention of haemolytic-uraemic syndrome.
Todd
W T
WT
Lanarkshire Area Infectious Diseases Unit, Monklands Hospital, Airdale, ML6 OJS, Lanarkshire, UK. andrew.todd@laht.scot.nhs.uk
D000900:Anti-Bacterial Agents / Q000627:therapeutic use; D004927:Escherichia coli Infections / Q000150:complications / Q000175:diagnosis / Q000635:transmission; D019453:Escherichia coli O157 / Q000187:drug effects / Q000472:pathogenicity; D006463:Hemolytic-Uremic Syndrome / Q000209:etiology / Q000517:prevention & control*; D006801:Humans; D008826:Microbial Sensitivity Tests; D011379:Prognosis; D022603:Shiga Toxins / Q000097:blood*; D014774:Virulence / Q000187:drug effects
D000900:Anti-Bacterial Agents; D022603:Shiga Toxins